- Home
- ACRE vs NBP Comparison
ACRE vs NBP Comparison
Compare ACRE & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | NBP |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 225.5M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRE | NBP |
|---|---|---|
| Price | $4.88 | $1.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.38 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 512.9K | 245.3K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | ★ 11.58% | N/A |
| EPS Growth | ★ 26.17 | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $54,833,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.28 | N/A |
| P/E Ratio | $3.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.14 | $1.46 |
| 52 Week High | $5.89 | $5.19 |
Technical Indicators
Market Signals| Indicator | ACRE | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 46.73 |
| Support Level | $4.67 | $1.67 |
| Resistance Level | $5.06 | $1.95 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 81.43 | 37.50 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a real estate investment trust mainly engaged in originating and investing in commercial real estate (CRE) loans and related investments. It operates in one segment, namely originating and managing a diversified portfolio of CRE debt-related investments. The company recognizes the majority of its revenues in the form of interest income, which it receives from loans.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.